Putative target for an immunotherapeutic approach to prevent, and stop the neurological and other symptoms of lesch-nyhan syndrome in humans: reconstructed cdna and protein antisense to the human hprt gene
CA 2087739 A1 · Owner: Bergmann, Johanna E. · Inventors: Bergmann, Johanna E.; Preddie, Rick E.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Point mutations and/ or deletions in the human hypoxanthineguanine phosphoribosyl transferase (HPRT) gene is believed to be the cause of Lesch-Nyhan syndrome in humans; however the, disastrous neurological symptoms which are characteristic of this disease cannot be easily explained by these mutations/deletions or even by the complete loss of the gene. There is no known cure for the disease. We reconstructed a cDNA (chprt) which is 100% homologous to a region of the antisense strand of hprt mRNA. The cDNA encodes a 30 amino acid protein (phrpt) which appears to be an intracellular activator of proteins involved in human neurological diseases. Because of the antisense relation with hprt mRNA, …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed January 25, 1993. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended January 25, 2013.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by January 25, 2015.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.